(주)셀렉스라이프사이언스

About Us

ILIAS is the Leader of Next-Generation Exosome Therapeutics.

2019
2019 Nov Received Ministerial Citation by Ministry of Health and Welfare, South Korea
Sep Established Scientific Advisory Board and held 1st Exosome in Medicine Symposium
Aug Selected for Future Medical Business One-Stop Support Initiative by Korea Health Industry Development Institute
Mar Received R21 NIH grant for exosome-based research
Relocated corporate headquarter to Daedeok Techno Valley, Daejeon, South Korea
Jan Established ILIAS Therapeutics, Inc. in New York, U.S.A.
2018
2018 May Series A funding (~$17M)
2017
2017 Nov Opened Pangyo research lab in Institute Pasteur Korea
Oct Opened Seoul office in Seoul Bio Hub
2016
2016 Sep 2nd angel funding
May Designated as K-Healthcare Start-Up by Korean Health Industry Development Institute
Feb 1st angel funding
2015
2015 Nov Incorporated in Daejeon, South Korea and certified as Venture Company with research facilities

개인정보취급방침

닫기

이메일주소무단수집거부

닫기

사이트맵

사이트맵

몬트리올의정서
국내이행법령
사업안내
특정물질 수출입
알림·자료실
민원서비스
닫기